Department of Gastroenterology, The First People's Hospital of Jingzhou, The First Affiliated Hospital of Yangtze University, Jingzhou, 434000, Hubei, China.
Department of Emergency, The First People's Hospital of Jingzhou, The First Affiliated Hospital of Yangtze University, Jingzhou, 434000, Hubei, China.
BMC Cancer. 2024 Sep 5;24(1):1110. doi: 10.1186/s12885-024-12590-2.
The prognosis of patients with hepatocellular cancer is substantially correlated with the abnormal expression of growing long non-coding RNA small nucleolar host gene RNA (SNHG) families in liver cancer tissues. This study aimed to examine the relationship between SNHG expression and liver cancer prognosis.
After searching six internet databases, pertinent manuscripts were found based on inclusion and exclusion criteria. To determine whether SNHG expression levels affect liver cancer prognosis, raw data were collected and hazard ratios (HRs) and odds ratios (ORs) were calculated. The results were examined for potential publication bias using the sensitivity analysis and Beeg's test.
Most SNHG family members were up-regulated in liver cancer tissues. High SNHG expression predicts poor liver cancer outcomes of, including overall survival (OS) (HR: 1.697, 95% confidence interval [CI]: 1.373-2.021), especially SNHG5 (the HR of OS is 4.74, 95%CI range from 1.35 to 6.64), progression-free survival (HR: 1.85, 95% CI: 1.25-2.73), tumor, node, metastasis (TNM) stage (OR: 1.696, 95% CI: 1.436-2.005), lymph node metastasis (OR: 2.383, 95% CI: 1.098-5.173), and tumor size (OR: 1363, 95% CI: 1.165-1.595). The OS results were found to be reliable and robust, as indicated by the sensitivity analysis. Additionally, Beeg's test demonstrated the absence of any potential publication bias for each result.
In liver cancer tissues, most SNHGs are highly expressed, which may signal poor prognosis. SNHG has the potential to be an intriguing predictive marker and a prospective therapeutic target for liver cancer.
肝癌患者的预后与肝癌组织中异常表达的长非编码 RNA 小核仁宿主基因 RNA(SNHG)家族密切相关。本研究旨在探讨 SNHG 表达与肝癌预后的关系。
通过检索六个互联网数据库,根据纳入和排除标准,找到了相关文献。为了确定 SNHG 表达水平是否影响肝癌预后,收集了原始数据,并计算了风险比(HRs)和优势比(ORs)。使用敏感性分析和 Beeg 检验来检测潜在的发表偏倚。
大多数 SNHG 家族成员在肝癌组织中上调。高 SNHG 表达预示着肝癌患者的预后不良,包括总生存期(OS)(HR:1.697,95%置信区间[CI]:1.373-2.021),尤其是 SNHG5(OS 的 HR 为 4.74,95%CI 范围为 1.35-6.64)、无进展生存期(HR:1.85,95%CI:1.25-2.73)、肿瘤、淋巴结、转移(TNM)分期(OR:1.696,95%CI:1.436-2.005)、淋巴结转移(OR:2.383,95%CI:1.098-5.173)和肿瘤大小(OR:1363,95%CI:1.165-1.595)。敏感性分析表明 OS 结果是可靠和稳健的。此外,Beeg 检验表明每个结果均不存在潜在的发表偏倚。
在肝癌组织中,大多数 SNHG 表达水平较高,可能预示着预后不良。SNHG 有可能成为肝癌有前途的预测标志物和治疗靶点。